• Managing Partner and co-founder of Columbus Venture Partners
  • Previous CEO of Highlight Therapeutics and Artax Biopharma
  • Founder of Highlight Therapeutics, Artax Biopharma, Viralgen, Vivet Therapeutics, Polypeptide Therapeutic Solutions, Tyris Therapeutics, and Radioterapia de Protones


Damià Tormo has spent the last 20 years working in healthcare and the biotech industry. He is currently Managing Partner and co-founder of Columbus Venture Partners, with three Funds in Biotech under management. He is founder of several biotech companies such as Highlight Therapeutics, Artax Biopharma, Viralgen (acquired by Bayer), Vivet Therapeutics (option by Pfizer), Polypeptide Therapeutic Solutions (acquired by Arcline), Tyris Therapeutics (partnership with Almirall) and Radioterapia de Protones (partnership with Quiron). He has also served as CEO of Highlight Therapeutics and Artax Biopharma Inc. for several years. Damia is currently Director of Artax, Highlight, Sanifit, Tyris, Algenex, Aleta and Syngoi. Moreover, Damia is the President of Fundación Columbus, a non-profit organization that develops advanced therapies for children with cancer and ultra-rare genetic diseases.

Before this, he was a researcher in different institutions such as the Uniklinik Bonn, University of Michigan or the Spanish National Cancer Center (CNIO). He received several awards related to innovation and entrepreneurship, including the 2017 Princess of Girona Foundation Award, TR35 from MIT or the Biogen Foundation Award. Damia holds a MSc in Biological Sciences from the University of Valencia, MBA from IE Business School and PhD in Immunology and Molecular Genetics from the Rheinische Friedrich-Wilhelms-Universität Bonn, Germany.